Matinas BioPharma Holdings Inc
AMEX:MTNB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Matinas BioPharma Holdings Inc
Current Portion of Long-Term Debt
Matinas BioPharma Holdings Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Matinas BioPharma Holdings Inc
AMEX:MTNB
|
Current Portion of Long-Term Debt
$2k
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Current Portion of Long-Term Debt
$6.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
12%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Current Portion of Long-Term Debt
$2.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Current Portion of Long-Term Debt
$4.6B
|
CAGR 3-Years
42%
|
CAGR 5-Years
119%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Matinas BioPharma Holdings Inc
Glance View
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 34 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform) to maximize global clinical impact and patient access. The Company’s lead anti-fungal product candidate, MAT2203, is an application of its LNC Platform to a broad spectrum and potent anti-fungal drug called amphotericin B. Its second clinical-stage LNC-based product candidate is MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including NTM, as well as various multidrug-resistant gram-negative and intracellular bacterial infections. The company also has internal discovery programs ongoing in the formulation and delivery of small oligonucleotides, namely antisense oligonucleotides (ASOs) and silencing or short interfering RNAs (siRNAs).
See Also
What is Matinas BioPharma Holdings Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
2k
USD
Based on the financial report for Dec 31, 2025, Matinas BioPharma Holdings Inc's Current Portion of Long-Term Debt amounts to 2k USD.
What is Matinas BioPharma Holdings Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
-42%
Over the last year, the Current Portion of Long-Term Debt growth was -60%. The average annual Current Portion of Long-Term Debt growth rates for Matinas BioPharma Holdings Inc have been -34% over the past three years , -42% over the past five years .
